1. Vremennye metodicheskie rekomendatsii po profilaktike, diagnostike i lecheniyu novoi koronavirusnoi infektsii (COVID-19) Minzdrava Rossii (versiya 17 ot 14.12.2022) [Interim guidelines for the prevention, diagnosis, and treatment of novel coronavirus infection (COVID-19) in Russia (version 17 of 12/14/2022)]. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/%D0%92%D0%9C%D0%A0_COVID-19_V17.pdf (Accessed 10 May 2023).
2. Radaeva O.A., Balykova L.A., Zaslavskaya K.Ya. et al. Izuchenie otdalennykh kliniko-patogeneticheskikh effektov protivovirusnogo lekarstvennogo preparata na osnove favipiravira v postkovidnom periode u patsientov s metabolicheskim sindromom [Study of long-term clinical and pathogenetic effects of favipiravir-based anti-viral drug in patients with metabolic syndrome in post-covid period]. Farmatsiya i farmakologiya, 2022, no. 10(2), pp. 217–228. DOI: 10.19163/2307-9266-2022-10-2-217-228.
3. Instruktsiya po primeneniyu lekarstvennogo preparata Esperavir® (molnupiravir) [Instructions for use of the drug Esperavir® (molnupiravir)]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=62a879e9-2c06-4028-8a58-5bac4e01d9ef (Accessed 10 May 2023).
4. Otkrytoe mnogotsentrovoe issledovanie po otsenke effektivnosti i bezopasnosti lekarstvennogo preparata Esperavir (molnupiravir), kapsuly (OOO «PROMOMED RUS», Rossiya) u vzrosloi populyatsii s COVID-19. Protokol issledovaniya: № MOL-112021 [Open Multicenter Study for Assessment of Efficacy and Safety of the the Drug Esperavir® (Molnupiravir), Capsules (PROMOMED RUS LLC, Russia) in Adult Patients With COVID-19. Clinical Trial Protocol: No. MOL-112021] Available at: https://ichgcp.net/ru/clinical-trials-registry/NCT05595824 (Accessed 10 May 2023).
5. Bakhitov V.V., Aliev S.R., Martsinkevich V.M. et al. Struktura smertnosti patsientov ambulatornogo tsentra v period pandemii novoi koronavirusnoi infektsii (COVID-19) [Structure of mortality among patients of an outpatient center during the pandemic of the new coronavirus infection (COVID-19)]. Sovremennye problemy zdravookhraneniya i meditsinskoi statistiki, 2022, no. 2, pp. 67–76. DOI: 10.24412/2312-2935-2022-2-67-76.